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Relatively speaking, antimalarial drug discovery from pheno-
typic whole cell screening has been far more successful than
target-based approaches in delivering selective antimalarial drug
candidates for a variety of reasons. It has recently been demon-
strated that chances of discovering cell permeable and active
antimalarials with potentially novel modes of action are signiﬁ-
cantly maximized through phenotypic screening. Compounds may
easily be dismissed from target-based screening approaches if the
desirable activity against the target is not achieved. The identiﬁ-
cation of novel antimalarial drug targets that may be relevant at
all stages of the malaria parasite life cycle has been challenging to
say the least. The absence of ready access to enabling technolo-
gies to allow the study of the malaria parasite life cycle stages
is in part responsible for this. Some of these technologies are
starting to emerge and are facilitating the discovery and evalua-
tion of novel drug targets. Within the context of the antimalarial
pipeline, although the currently available chemotherapeutic arma-
mentarium for malaria is severely limited, re-engagement of the
pharmaceutical industry through precompetitive research consor-
tia in which there are shared resources and costs, thus mitigating
the risks involved in drug discovery, is signiﬁcantly changing the
landscape as recently demonstrated throughpartnerships between
the pharmaceutical industry and not-for-proﬁt Product Develop-
ment Partnerships (PDPs) such as Medicines for Malaria Venture
(MMV). This lecture will address platform technologies and how
these have been utilized in the discovery of novel antimalarial
drug targets. An update on the antimalarial pipeline will also be
presented. In conclusion, new and emerging enabling technologies
have facilitated the discovery of novel antimalarial drug targets and
boosted the antimalarial pipeline.
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Insecticide resistance: will mosquitoes be our
nemesis?
M. Coetzee
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Malaria parasites are transmitted to humans by anopheline
mosquitoes. The parasite undergoes an obligatory sexual stage
within the mosquito midgut that takes up to 14 days to com-
plete. This presents a window of opportunity for us to control the
mosquito populations before they have sufﬁcient time to become
infective. Unfortunately, both mosquitoes and parasites have been
around a lot longer than humans and so far have managed to ﬁnd
ways of getting around all the drugs and insecticides thatwe throw
at them. In Africa today there are approximately 140 recognised
species of Anopheles mosquitoes. Only 4 of these are really good
vectors of malaria parasites and are widespread over the conti-
nent. Three of them are highly adapted to humans and human
habitations and should, therefore, be easy to control using current
technology. The fourth is more cosmopolitan and is equally happy
to feed on cattle as well as humans and rest both indoors and out-
doors, making it a much more difﬁcult vector to control. All four
species have developed high levels of resistance to the insecticides
we use for vector control and given the limited number of chemi-
cals that are approved by the World Health Organization for vector
control, there is an urgent need for new and innovative methods
for controlling malaria vector mosquitoes.
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The increase of Mycobacterium tuberculosis
drug resistance in low and middle-income
countries
W. Van Gemert
WHO, Geneva, Switzerland
Background: Drug-resistant TB, and particularly multidrug-
resistant TB (MDR-TB) that is resistant to rifampicin and isoniazid,
is a major public health problem that threatens progress made in
TB care and control worldwide. WHO estimates that there were
450,000 (range: 300,000-600,000) new cases of MDR-TB world-
wide in 2012.
Objective:Topresent aglobalupdateonanti-TBdrug-resistance
surveillance.
